Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INT2104 · 1 trial · 2 indications
Number of Participants With Adverse Events as Assessed by CTCAE v5.0
Number of Participants With abnormal clinical laboratory values as Assessed by CTCAE v5.0
Number of participants experiencing Cytokine Release Syndrome (CRS)
Number of participants experiencing Immune Effector Cell Neurotoxicity (ICANS)
Number of participants experiencing dose-limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| INT2104 Dose Level 1 | EXPERIMENTAL | Single IV administration of INT2104 |
| INT2104 Dose Level 2 | EXPERIMENTAL | Single IV administration of INT2104 |
| INT2104 Dose Level 3 | EXPERIMENTAL | Single IV administration of INT2104 |
| INT2104 Dose Level 4 | EXPERIMENTAL | Single IV administration of INT2104 |
| INT2104 Recommended Dose | EXPERIMENTAL | Single IV administration of INT2104 |
| Name | Type | Description |
|---|---|---|
| INT2104 | GENETIC | INT2104 is a lentiviral vector delivering a transgene for a chimeric antigen receptor specific for CD20 (CAR20) |
Inclusion Criteria: * Diagnosed with relapsed/refractory (R/R) B-NHL (Burkitt's lymphoma are eligible for Part B only) confirmed by histology or flow cytometry Note: Bone Marrow involvement is allowed * B-NHL must have CD20 antigen positive tumour confirmed from a tumour biopsy taken at screening *...
INT2104 is an investigational gene therapy being studied for the treatment of B-cell cancers, specifically non-Hodgkin's B-cell lymphomas and precursor cell lymphoblastic leukemia-lymphoma. It is intended for patients aged 18 years and older whose cancer has returned after previous treatment.
INT2104 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is currently sponsoring a Phase 1 clinical trial to investigate the safety of the therapy.
INT2104 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being evaluated for safety and efficacy in clinical trials.
INT2104 is being studied in a single Phase 1 clinical trial registered as NCT06539338. This trial is active but not recruiting participants, with a planned enrollment of 10 patients. The study is being conducted at sites in Australia and Spain.
INT2104 is the primary name for this investigational gene therapy. No alternative names have been associated with this drug in the available clinical trial information.